Gavin Megaw resigned as head of Hanover PR after US embassy objected to his Trump criticism
The US embassy demanded APG fire Hanover or face losing diplomatic cooperation
Megaw's deleted posts included remarks about Trump's press conferences and international relations
The UK agreed to increase pharmaceutical spending by 25% following US pressure
📖 Full Retelling
Gavin Megaw, the head of UK PR company Hanover representing American drugmakers, resigned from his position in late January 2026 after the US embassy in London raised concerns about his online posts criticizing President Donald Trump, who has lobbied for Britain to increase spending on medicines. Megaw's exit followed a complaint from the embassy to the American Pharmaceutical Group (APG), which represents major pharmaceutical companies including Eli Lilly, Johnson & Johnson and Gilead in the UK and employs Hanover for strategic communications. The embassy had been instrumental in pressuring the UK government to increase NHS spending on drugs after Trump accused European countries of 'freeloading' off US innovation and threatened pharmaceutical tariffs. The specific posts that triggered the controversy, which have since been deleted but remain visible on Google, included comments about a 'ludicrously meandering press conference' by Trump and references to the 'Trump Trap' regarding international relations, particularly over the Chagos Islands. A source familiar with the matter revealed that the US embassy was 'hopping mad' over the posts, with the clear implication that their cooperation with the APG would be affected unless Hanover was terminated. The pharmaceutical industry has simultaneously pushed UK ministers to increase drug payments while complaining about an unexpected surge in a clawback tax on their UK sales, creating a complex landscape of international diplomacy and corporate interests.
🏷️ Themes
Diplomatic Relations, Corporate Communications, Pharmaceutical Industry
President of the United States (2017–2021; since 2025)
Donald John Trump (born June 14, 1946) is an American politician, media personality, and businessman who is the 47th president of the United States. A member of the Republican Party, he served as the 45th president from 2017 to 2021.
Born into a wealthy New York City family, Trump graduated from the...
This case highlights how foreign diplomatic pressure can directly impact corporate employment decisions and freedom of expression. It demonstrates the significant influence the US embassy wields over UK business relationships, particularly in sensitive sectors like pharmaceutical pricing. The incident raises questions about the boundaries between professional conduct and political speech in international business relations.
Context & Background
US President Trump criticized European countries for freeloading off US drug innovation
US embassy pressured UK government to increase NHS spending on medicines
Hanover PR firm represented American Pharmaceutical Group in UK
Trump administration threatened pharmaceutical tariffs against allies
What Happens Next
Hanover will complete its current contract with APG but will not have its contract renewed. The US embassy will likely maintain its close relationship with APG and continue influencing UK pharmaceutical pricing policy. This case may prompt discussions about corporate policies regarding employees personal political expressions.
Frequently Asked Questions
Who was the PR executive involved?
Gavin Megaw, who was president and managing director of Hanover Communications.
What prompted the US embassy complaint?
Megaw's LinkedIn posts criticizing President Trump, including comments about a ludicrous press conference and the Chagos Islands situation.
What was the outcome for Hanover?
Hanover lost the APG account after the US embassy threatened to cease dealings with the pharmaceutical group.
What is the broader context of US-UK pharmaceutical relations?
The US has been pressuring the UK to increase NHS drug spending, resulting in a recent agreement for 25% more investment in medicines.
Original Source
UK PR executive left role after US embassy raised concerns over online posts on x (opens in a new window) UK PR executive left role after US embassy raised concerns over online posts on facebook (opens in a new window) UK PR executive left role after US embassy raised concerns over online posts on linkedin (opens in a new window) UK PR executive left role after US embassy raised concerns over online posts on whatsapp (opens in a new window) Save UK PR executive left role after US embassy raised concerns over online posts on x (opens in a new window) UK PR executive left role after US embassy raised concerns over online posts on facebook (opens in a new window) UK PR executive left role after US embassy raised concerns over online posts on linkedin (opens in a new window) UK PR executive left role after US embassy raised concerns over online posts on whatsapp (opens in a new window) Save Anna Gross in London Published February 24 2026 Jump to comments section Print this page Unlock the White House Watch newsletter for free Your guide to what Trump’s second term means for Washington, business and the world The head of a UK PR company representing American drugmakers left his job after the US embassy in London raised concerns about online posts in which he criticised President Donald Trump, who has lobbied for Britain to spend more on medicines. Gavin Megaw’s exit from Hanover last month came after the US embassy ceased contact with the PR firm and complained about his LinkedIn posts to the American Pharmaceutical Group, according to a document seen by the FT and a person familiar with the matter. The APG — which represents drugmakers such as Eli Lilly, Johnson & Johnson and Gilead in the UK and uses Hanover to provide strategic communications — was concerned about damage to its relationship with the US embassy, the person said. The embassy has been instrumental in forcing the UK government to increase NHS spending on drugs after Trump accused European countries of “fr...
